image credit: Unsplash

Biotech company wins Merck award for platform to help treat muscular and neurodegenerative disorders

May 21, 2021

VectorY was chosen for its development of proprietary and partnered programs based on a novel adeno-associated viruses (AAV) platform for the treatment of muscular and neurodegenerative disorders.

The company currently has a pipeline of vectorized antibodies, including two in pre-clinical development, targeting muscular and central nervous system diseases with unmet needs. Its vectors and bioprocess technologies aim to help scale manufacturing processes for flexible production and overcome current challenges in the delivery and manufacturability for advanced gene therapies.

Read More on EPM Magazine